Clockwise from left: Merida Biosciences CSO Dario Gutierrez, COO Dodzie Sogah, CEO Adam Townsend and CMO Matt Leoni
April 8, 2025 07:00 AM EDT
Financing
Startups

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Kyle LaHucik

Senior Reporter

A scrap­py team of drug de­vel­op­ers has come to­geth­er to cre­ate new med­i­cines for pa­tients with au­toim­mune dis­eases and al­ler­gies. They’re go­ing af­ter the bustling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

A service from the Financial Times